Phenobarbital specific antisera and radioimmunoassay

Résumé On a développé un anticorps d'une grande affinité et spécifité envers le phénobarbital en inoculant des lapins avec une solution de barbiturateprotéide, synthétisée d'acide barbiturique de 5-phényl-5-(4-aminobutyl) et d'albumine de sérum bovin par du carbodiimide. Usant de cet anticorps comme radioimmunoeassai, on peut mesurer jusqu'à 1 picomole de phénobarbital par ml de fluides biologique sans que d'autres barbiturates y opposent une réaction significative.

---

---

We express our appreciation to the Lilly Research Laboratories for the donation of amobarbital and secobarbital.     

Inhibition of phosphoglucomutase by galactose 1,6-diphosphate

Zusammenfassung Chemisch synthetisiertes Galaktose-1,6-Diphosphat wird als Hemmer dès Glukose-1,6-Di-phosphats in der Phosphoglukomutase-Reaktion bestimmt.     

The DNA sequence and analysis of human chromosome 13

Chromosome 13 is the largest acrocentric human chromosome. It carries genes involved in cancer including the breast cancer type 2 (BRCA2) and retinoblastoma (RB1) genes, is frequently rearranged in B-cell chronic lymphocytic leukaemia, and contains the DAOA locus associated with bipolar disorder and schizophrenia. We describe completion and analysis of 95.5 megabases (Mb) of sequence from chromosome 13, which contains 633 genes and 296 pseudogenes. We estimate that more than 95.4% of the protein-coding genes of this chromosome have been identified, on the basis of comparison with other vertebrate genome sequences. Additionally, 105 putative non-coding RNA genes were found. Chromosome 13 has one of the lowest gene densities (6.5 genes per Mb) among human chromosomes, and contains a central region of 38 Mb where the gene density drops to only 3.1 genes per Mb.     

Physiology: does gut hormone PYY3-36 decrease food intake in rodents?

Batterham et al. report that the gut peptide hormone PYY3-36 decreases food intake and body-weight gain in rodents, a discovery that has been heralded as potentially offering a new therapy for obesity. However, we have been unable to replicate their results. Although the reasons for this discrepancy remain undetermined, an effective anti-obesity drug ultimately must produce its effects across a range of situations. The fact that the findings of Batterham et al. cannot easily be replicated calls into question the potential value of an anti-obesity approach that is based on administration of PYY3-36.